Acute myeloid leukemia and myelodysplastic syndromes related to topoisomerase type 2 inhibitor Advocacy Hub | UniteRare

Regulatory Watchboard

No FDA or trial events recorded yet for Acute myeloid leukemia and myelodysplastic syndromes related to topoisomerase type 2 inhibitor.

Financial Assistance

1 program

FINANCIAL LANDSCAPE SUMMARY

Total programs

Open now

Patient Assistance Programs1

Synribo

IVAX International GmbH

OpenContact for details

View all support programs on disease page →

Approved Treatments

2 FDA-approved

Synribo

(omacetaxine mepesuccinate)Orphan drugaccelerated

IVAX International GmbH

Imatinib Mesylate

(IMATINIB MESYLATE)Orphan drugstandard

Apotex Corp

12.1 Mechanism of Action Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the BCR-ABL tyrosine kinase, the constitutive abnormal...

FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for Acute myeloid leukemia and myelodysplastic syndromes related to topoisomerase type 2 inhibitor.
Search all trials →

Search clinical trials for Acute myeloid leukemia and myelodysplastic syndromes related to topoisomerase type 2 inhibitor →